June 20, 2013 3:59 AM ET

Biotechnology

Company Overview of MedImmune, LLC

Company Overview

MedImmune, LLC, a biotechnology company, engages in the research, development, and commercialization of biological products, and therapeutic and preventive medicines for use in the areas of infectious diseases, oncology, respiratory diseases, inflammation, cardiovascular/gastrointestinal diseases, and neuroscience. Its products include Synagis, a monoclonal antibody that is used for the prevention of serious lower respiratory tract disease caused by RSV in children; FluMist, a nasal spray flu vaccine that is used for the active immunization of eligible individuals between 2 to 49 years of age against influenza disease caused by influenza virus subtypes A and B contained in the vaccine; and E...

Detailed Description

One MedImmune Way

Gaithersburg, MD 20878

United States

Founded in 1988

2,359 Employees

Phone:

301-398-0000

Fax:

301-527-4200

www.medimmune.com

Key Executives for MedImmune, LLC

President
Age: 41
Chief Financial Officer and Senior Vice President
Age: 44
Executive Vice President of Operations
Age: 51
Vice President
Chief Information Officer and Vice President
Compensation as of Fiscal Year 2012.

MedImmune, LLC Key Developments

MedImmune and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
Jun 17 13

AstraZeneca announced that MedImmune and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM's enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity. EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the known GI hormones, including GLP-1. EECs are an underexplored source of novel hormones that could play a major role in the positive and negative regulation of metabolism and glucose homeostasis. NGM has established a proprietary platform capable of isolating and analysing EECs in order to identify novel secreted peptide hormones that are potentially linked to the profound metabolic effects of bariatric surgery and serve as potential targets for the treatment of metabolic diseases. MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones. MedImmune will have the option to license in these EEC targets, and will be responsible for the global development, manufacture and commercialisation of compounds resulting from the collaboration. Under the terms of the agreement, MedImmune will make an upfront payment and provide NGM research funding over the course of the collaboration. If certain development, regulatory and commercial milestones are achieved, NGM will be entitled to receive various payments, as well as royalties on worldwide product sales.

MedImmune, LLC Presents at 2013 BIO International Convention, Apr-23-2013 08:45 AM
Apr 18 13

MedImmune, LLC Presents at 2013 BIO International Convention, Apr-23-2013 08:45 AM. Venue: McCormick Place - Chicago Bulls Room, 2301 S. Lake Shore Drive, Chicago, IL 60616, United States.

MedImmune, LLC Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013
Dec 19 12

MedImmune, LLC Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 . Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.

Similar Private Companies By Industry

Company Name Region
Novella Clinical, Inc. United States
MolecularMD Corp. United States
L.N.K. International Inc. United States
Chemizon Inc. United States
ROXRO PHARMA, Inc. United States

Recent Private Companies Transactions

Type
Date		 Target
Merger/Acquisition
April 3, 2013 		AlphaCore Pharma LLC
Report Data IssueReport Data Issue
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune, LLC, please visit www.medimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.

Close